Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2002 (LINC02002) is a member of the long non-coding RNA (lncRNA) family, specifically classified as a long intergenic non-coding RNA (lincRNA)[1][3]. LincRNAs are autonomously transcribed RNA molecules over 200 nucleotides in length that do not overlap annotated protein-coding genes[3][5]. While the specific function and disease relevance of LINC02002 have not been characterized, lincRNAs in general have been shown to play roles in chromatin remodeling, regulation of gene expression in *cis* or *trans*, and possibly in cellular differentiation and development. Some lincRNAs function as enhancers or scaffolds for chromatin-modifying complexes, and they are under active investigation for their roles in cancer and other diseases[3][5]. There is currently **no evidence to support LINC02002 as a direct therapeutic target, biomarker, or established disease gene**[1]. LINC02002 is a long non-coding RNA of the lincRNA subtype with no documented function or therapeutic relevance as of current knowledge; it does not function as a receptor, enzyme, transporter, or drug target[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2002 (LINC02002).